Merck KGaA budgets $1.58B for drug R&D
With about 40 drug development projects in the pipeline, Germany's Merck KGaA says it will spend about €1 billion ($1.58 billion) on drug research this year. That R&D budget represents about 22 percent of sales and is a big increase on last year's budget of €890 million. Merck officials say they're out to sell their diabetes research division, and plan to focus on four key areas: cancer, infertility, nervous system and autoimmune diseases.
- check out the AFX report
Related Articles:
Merck KGaA CEO eyes new acquisitions
Mylan inks $6.6B deal for Merck's generic drug biz
Merck KGaA buying control of Serono
Be the first to comment Rate it:
Comments
Post new comment
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight